3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Phase 2
1
Status
Recruiting
1
Active not recruiting
1
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Interventional
2
Sponsor
Cancer Type
NET
2
Gastrointestinal
2
Endocrine
2
Conditions
Colorectal Neoplasms
9
Pancreatic Neoplasms
6
Ovarian Neoplasms
5
Sarcoma
4
Neuroblastoma
4
Liver Neoplasms
4
Wilms Tumor
3
Somatostatinoma
3
Rectal Neoplasms
3
Osteosarcoma
3
Neuroendocrine Tumors
3
Neuroectodermal Tumors, Primitive, Peripheral
3
Neoplasms
3
Medulloblastoma
3
Gastrointestinal Stromal Tumors
3
Esophageal Neoplasms
3
Astrocytoma
3
Zollinger-Ellison Syndrome
2
Vipoma
2
Testicular Neoplasms
2
Teratoma
2
Sarcoma, Ewing
2
Rhabdomyosarcoma
2
Rhabdoid Tumor
2
Pheochromocytoma
2
Ovarian Germ Cell Cancer
2
Optic Nerve Glioma
2
Oligodendroglioma
2
Neoplasm Metastasis
2
Melanoma
2
Interventions
lutetium Lu 177 dotatate
8
lanreotide
4
copper dotatate CU-64
4
Octreotide
4
177Lu-octreotide, DOTA(0)-Tyr(3)-
4
pasireotide
3
Magnetic Resonance Spectroscopy
3
Lutetium-177
3
Lutetium
3
gallium Ga 68 dotatate
2
amino-acid, glucose, and electrolyte solution
2
Temozolomide
2
Nivolumab
2
Irinotecan
2
Ga(III)-DOTATOC
2
Everolimus
2
Etoposide
2
Carboplatin
2
zimberelimab
1
regorafenib
1
pembrolizumab
1
irinotecan sucrosofate
1
folfirinox
1
famitinib
1
cabozantinib
1
arginyllysine
1
abemaciclib
1
X-Rays
1
Sunitinib
1
Somatostatin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Gastro-enteropancreatic neuroendocrine tumor
×
Temozolomide
×
Gastrointestinal
×
Clear all
NCT04919226
2025-09-10
COMPOSE
ITM Solucin GmbH
Phase 3
Active not recruiting
259 enrolled
NCT04893785
2024-06-18
CABOTEM
National Cancer Institute, Naples
Phase 2
Recruiting
35 enrolled